PracticeVideosBlogFlashcardsEspañol
All Practice Exams

Free Practice Questions for Egyptian Board Gastroenterology & Hepatology

Exam-style questions and explanations by OpenExamPrep.

✓ No registration✓ No credit card
100+ Questions
100% Free

Loading practice questions...

Same family resources

Explore More Egyptian Board Specialty Certifications (البورد المصري)

Continue into nearby exams from the same family. Each card keeps practice questions, study guides, flashcards, videos, and articles in one place.

Egyptian Board — Anesthesia (Part 1 & 2)

Practice Questions

Egyptian Board — Cardiology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Infectious Diseases (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Oncology (Part 1 & 2)

Practice Questions

Egyptian Board — Clinical Pathology (Part 1 & 2)

Practice Questions

Egyptian Board — Critical Care (Part 1 & 2)

Practice Questions

Sample Egyptian Board Gastroenterology & Hepatology Practice Questions

Try these sample questions to review concepts for the Egyptian Board Gastroenterology & Hepatology exam. Each question includes a detailed explanation. Start the interactive quiz above for the full 100+ question experience with AI tutoring.

1A 42-year-old woman presents with persistent retrosternal heartburn and acid regurgitation refractory to standard-dose esomeprazole (40 mg once daily) taken 30 minutes before breakfast for 12 weeks. Upper gastrointestinal endoscopy reveals normal esophageal mucosa (Los Angeles grade 0) without hiatal hernia. What is the most appropriate next diagnostic investigation according to international and Egyptian consensus guidelines?
A.Ambulatory 24-hour pH-impedance monitoring performed while off proton pump inhibitor therapy
B.Empiric escalation to twice-daily dexlansoprazole 60 mg combined with bedtime famotidine
C.High-resolution esophageal manometry followed immediately by laparoscopic Nissen fundoplication
D.Barium swallow esophagram with solid barium tablet ingestion in the upright and prone positions
Explanation: In patients with typical reflux symptoms refractory to PPI therapy and normal upper endoscopy (unproven GERD), ambulatory 24-hour pH-impedance monitoring performed off PPI therapy (for at least 7 days) is the diagnostic gold standard. This study determines objective acid exposure time (AET), reflux episodes, and symptom-reflux association, effectively distinguishing true non-erosive reflux disease (NERD), reflux hypersensitivity, and functional heartburn. Testing on-therapy is reserved for patients with previously objectively confirmed GERD.
2During screening endoscopy for chronic GERD in a 58-year-old man, salmon-colored columnar epithelium extending above the gastroesophageal junction is visualized. Applying the validated Prague C & M Criteria, how should the endoscopist document this finding?
A.Measure the distance from the incisors to the squamocolumnar junction and subtract the hiatal hernia length
B.Record the circumferential extent (C) and the maximal longitudinal extent (M) of metaplastic epithelium in centimeters above the gastroesophageal junction
C.Record the total number of mucosal tongue projections and categorize the lesion as short-segment if under two centimeters
D.Calculate the surface area of columnar metaplasia using narrow-band imaging software planimetry
Explanation: The Prague C & M criteria standardize the endoscopic grading of Barrett esophagus by measuring the circumferential extent (C) and maximal extent (M) of columnar epithelium in centimeters above the gastroesophageal junction (the proximal limit of gastric folds). For example, a segment with 2 cm circumferential metaplasia and tongues extending to 5 cm is documented as C2M5. This standardized classification has high inter-observer reliability and guides surveillance intervals.
3A 62-year-old man with a Prague C3M5 segment of Barrett esophagus undergoes four-quadrant biopsies every 2 cm (Seattle protocol). Histopathology reports intestinal metaplasia with low-grade dysplasia (LGD). What is the mandatory next clinical step before deciding between endoscopic eradication therapy and surveillance?
A.Immediate radiofrequency ablation (RFA) without further pathological evaluation
B.Endoscopic submucosal dissection (ESD) of the entire circumferential segment
C.Review and confirmation of the low-grade dysplasia diagnosis by a second expert gastrointestinal pathologist
D.Repeat surveillance upper endoscopy with targeted biopsies in twelve months
Explanation: Because inter-observer variability in diagnosing low-grade dysplasia (LGD) in Barrett esophagus is notorious, all major clinical guidelines (ACG, BSG, ESGE) require confirmation of dysplasia by at least one independent expert gastrointestinal pathologist. In up to 70% of cases, non-expert diagnoses of LGD are downstaged to non-dysplastic Barrett esophagus or indefinite for dysplasia upon expert review. Once expert confirmation of LGD is established, endoscopic eradication therapy (RFA) is preferred over surveillance due to significant risk reduction of progression to HGD/adenocarcinoma.
4A 66-year-old man with known Barrett esophagus (Prague C4M7) undergoes surveillance endoscopy. High-definition white-light examination with narrow-band imaging reveals an 8 mm slightly elevated mucosal nodule (Paris 0-IIa) at the 4 o'clock position. Four-quadrant biopsies from the flat background mucosa demonstrate high-grade dysplasia (HGD). What is the optimal multimodal management strategy?
A.Transhiatal esophagectomy with two-field lymph node dissection and gastric pull-up
B.Circumferential radiofrequency ablation (RFA) applied directly over the nodule and flat mucosa simultaneously
C.Photodynamic therapy combined with systemic fluoropyrimidine-based chemoradiotherapy
D.Endoscopic mucosal resection (EMR) of the visible nodule followed by radiofrequency ablation (RFA) of all remaining flat Barrett mucosa
Explanation: The current standard of care for Barrett esophagus with high-grade dysplasia and visible lesions is initial endoscopic resection (EMR or ESD) of all discrete visible mucosal abnormalities, which provides accurate histological staging (assessing depth of invasion, lymphovascular involvement, and margin status), followed by ablation (typically radiofrequency ablation, RFA) of all remaining flat columnar metaplasia to eliminate metachronous neoplasia. Esophagectomy carries significant morbidity/mortality and is reserved for invasive submucosal carcinoma (T1b) or failed endoscopic therapy.
5A 34-year-old man presents with progressive solid and liquid dysphagia, regurgitation of undigested food, and an 8 kg weight loss over 9 months. High-resolution manometry (HRM) using the Chicago Classification version 4.0 demonstrates an integrated relaxation pressure (IRP) of 28 mmHg (normal < 15 mmHg) and 100% failed peristalsis (distal contractile integral [DCI] < 100 mmHg·s·cm) across all ten test swallows, with no esophageal pressurization. Which motility disorder is diagnosed?
A.Type I (classic) achalasia
B.Type II (pan-esophageal pressurization) achalasia
C.Type III (spastic) achalasia
D.Absent contractility with normal lower esophageal sphincter relaxation
Explanation: According to the Chicago Classification version 4.0, achalasia requires an elevated median integrated relaxation pressure (IRP) along with absent normal peristalsis. Type I (classic) achalasia is defined by an elevated median IRP, 100% failed peristalsis (DCI < 100 mmHg·s·cm), and no esophageal pressurization in >= 80% of swallows. In contrast, Type II exhibits pan-esophageal pressurization in >= 20% of swallows, and Type III exhibits premature/spastic contractions (distal latency < 4.5 s with DCI > 450 mmHg·s·cm) in >= 20% of swallows.
6A 28-year-old woman is diagnosed with Type II achalasia based on an elevated median IRP of 32 mmHg and pan-esophageal pressurization in 60% of wet swallows. Which statement regarding the clinical course and therapeutic response of Type II achalasia compared to Types I and III is correct?
A.Type II achalasia has the lowest response rate to all treatment modalities and frequently requires early esophagectomy
B.Type II achalasia exhibits the most favorable response to treatment, with over 90% success following pneumatic dilation, Heller myotomy, or POEM
C.Type II achalasia responds uniquely to botulinum toxin injection, which confers durable lifelong symptom remission
D.Type II achalasia is exclusively caused by secondary pseudoachalasia from gastroesophageal junction adenocarcinoma
Explanation: Type II achalasia (characterized by pan-esophageal pressurization resulting from trapped bolus between a non-relaxing upper and lower esophageal sphincter) carries the most favorable prognosis among all achalasia subtypes. Clinical success rates exceed 90% across pneumatic dilation (PD), laparoscopic Heller myotomy (LHM), and peroral endoscopic myotomy (POEM). Type I has intermediate response rates (~70-80%), while Type III has the poorest response to standard pneumatic dilation or standard short surgical myotomy.
7A 48-year-old man undergoes high-resolution manometry for severe chest pain and dysphagia. Findings show an elevated median IRP of 26 mmHg and 40% premature (spastic) contractions with distal latency < 4.5 seconds and DCI > 5000 mmHg·s·cm, confirming Type III (spastic) achalasia. Which intervention has demonstrated superior clinical efficacy over laparoscopic Heller myotomy (LHM) and pneumatic dilation for this specific subtype?
A.Serial large-diameter (40 mm) pneumatic balloon dilations spaced four weeks apart
B.Surgical laparoscopic Nissen fundoplication without myotomy
C.Peroral endoscopic myotomy (POEM) allowing tailored, extended proximal esophageal myotomy
D.Chronic high-dose calcium channel blocker therapy combined with sublingual nitrates
Explanation: Type III achalasia involves spastic, non-propagating contractions extending high into the esophageal smooth muscle body. Peroral endoscopic myotomy (POEM) is the preferred treatment modality because it allows the operator to tailor the length of the esophageal myotomy proximally into the mid-esophagus (often 10-15 cm) to encompass the entire spastic segment identified on manometry. Laparoscopic Heller myotomy is surgically limited by the diaphragmatic hiatus to approximately 6-8 cm of esophageal myotomy, resulting in significantly lower response rates (~60% vs >90% for POEM in Type III).
8According to the Chicago Classification version 4.0, which manometric criteria are required to establish the definitive diagnosis of distal esophageal spasm (DES)?
A.Elevated median IRP with >= 20% premature swallows (distal latency < 4.5 s)
B.Normal median IRP with >= 20% hypercontractile swallows (DCI > 8000 mmHg·s·cm)
C.Elevated median IRP with 100% absent peristalsis and pan-esophageal pressurization
D.Normal median IRP with >= 20% premature swallows (distal latency < 4.5 s) in the presence of clinically relevant symptoms
Explanation: In Chicago Classification v4.0, distal esophageal spasm (DES) is defined by a normal lower esophageal sphincter relaxation (normal median integrated relaxation pressure, IRP) combined with >= 20% premature contractions (distal latency < 4.5 seconds with DCI > 450 mmHg·s·cm) during ten supine wet swallows, accompanied by clinically relevant symptoms (dysphagia and/or non-cardiac chest pain). If the median IRP were elevated, the diagnosis would be Type III achalasia rather than DES.
9A 24-year-old atopic man presents with intermittent solid food dysphagia and a single episode of meat bolus impaction requiring endoscopic disimpaction. Upper endoscopy reveals stacked circular rings ('trachealization'), linear furrows, and white exudative plaques. Esophageal biopsies show 35 eosinophils per high-power field (HPF). What is the first-line pharmacotherapeutic approach recommended by international and Egyptian GI guidelines?
A.Swallowed topical corticosteroids (e.g., fluticasone spray or oral budesonide slurry/orodispersible tablet) or high-dose PPI therapy
B.Systemic high-dose oral prednisone (1 mg/kg daily) for six months followed by maintenance azathioprine
C.Empiric surgical esophagectomy with cervical esophagogastric anastomosis
D.Immediate serial pneumatic balloon dilations up to 35 mm without medical therapy
Explanation: Eosinophilic esophagitis (EoE) is diagnosed by symptoms of esophageal dysfunction and esophageal mucosal biopsies showing >= 15 eosinophils/HPF in the absence of non-EoE causes. First-line treatments include proton pump inhibitors (high-dose twice daily for 8-12 weeks) and swallowed topical corticosteroids (e.g., budesonide orodispersible tablets or fluticasone). Both modalities induce clinical and histological remission in 50-70% of patients. Monoclonal antibody therapy targeting IL-4/IL-13 (dupilumab) is approved for refractory or severe cases.
10A 45-year-old woman with suspected peptic ulcer disease is scheduled for non-invasive Helicobacter pylori testing. To avoid false-negative results on urea breath testing (UBT) and stool antigen testing, what is the mandatory minimum withdrawal period for proton pump inhibitors (PPIs) and antibiotics/bismuth compounds, respectively?
A.No withdrawal needed for PPIs; 1 week withdrawal for antibiotics
B.Withdraw PPIs for at least 2 weeks; withdraw antibiotics and bismuth for at least 4 weeks
C.Withdraw PPIs for 24 hours; withdraw antibiotics for 7 days
D.Withdraw both PPIs and antibiotics for exactly 12 weeks
Explanation: PPIs suppress H. pylori bacterial load and urease activity, leading to false-negative urea breath tests and stool antigen tests; therefore, PPIs must be held for at least 2 weeks prior to testing (H2-receptor antagonists may be substituted and held 24-48 hours before). Antibiotics and bismuth have direct antimicrobial effects and must be discontinued for at least 4 weeks before testing. Serology (IgG antibodies) is not affected by medications but cannot differentiate active from past infection.

About the Egyptian Board Gastroenterology & Hepatology Exam

The Egyptian Board in Gastroenterology and Hepatology is the premier clinical subspecialty certification administered by the Egyptian Health Council (المجلس الصحي المصري) under Law No. 12 of 2022. It validates expert clinical acumen in luminal GI disorders, hepatobiliary diseases, portal hypertension, viral hepatitis, inflammatory bowel diseases, and diagnostic/therapeutic endoscopy. The examination pathway comprises three progressive phases: Part 1 written basic sciences, Part 2 written clinical specialty, and Part 3 comprehensive clinical OSCE, endoscopy image interpretation, and oral viva voce.

Exam sponsor: Egyptian Health Council (EHC) — Egyptian Board (المجلس الصحي المصري — البورد المصري). The requirements and fees below concern the certification or admission exam, separate from our free practice resources.

Assessment

The Egyptian Board Gastroenterology and Hepatology examination comprises three stages: Part 1 features written multiple-choice questions assessing GI physiology, hepatic anatomy/blood flow, pathology, microbiology, and pharmacology. Part 2 features advanced clinical multiple-choice examinations evaluating real-world diagnostic algorithms, BCLC staging for HCC, IBD biologic sequencing, and acute variceal bleed management. Part 3 is a comprehensive clinical examination consisting of objective structured clinical examination (OSCE) stations, patient consultations, endoscopic video interpretation, and viva voce with senior academic examiners. Note that Part Three is entirely clinical, and the official board does not publish a standardized MCQ question count. This 100-question practice set is an English-language study aid dedicated to reinforcing key cognitive knowledge across Parts 1 and 2.

Time Limit

Varies by examination part

Passing Score

Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published

Exam / Certification Fees

Prescribed by Egyptian Health Council regulatory bylaws

Exam sponsor website

Fees, eligibility, and exam policies can change. Confirm them with the exam sponsor before applying or paying.

Our practice resources: topics covered

We aim to reflect publicly available exam outlines and topic information in our study resources. Coverage, format, and difficulty may differ from the actual exam, and we cannot guarantee that every detail is accurate or current. Confirm exam requirements, fees, and policies with the official exam sponsor.

20%

Esophagus, Stomach & Upper GI Disorders

Gastroesophageal reflux disease (GERD) and Barrett esophagus; motility disorders (achalasia, diffuse esophageal spasm, gastroparesis); peptic ulcer disease and Helicobacter pylori eradication protocols; upper GI bleeding etiology and endoscopic management; gastric malignancies.

20%

Intestinal Disorders, Malabsorption & IBD

Celiac disease, tropical sprue, and small intestinal bacterial overgrowth (SIBO); Crohn disease and ulcerative colitis (phenotypes, Montreal classification, biologic therapies, surveillance); irritable bowel syndrome (Rome IV); lower GI bleeding; colorectal polyps and hereditary cancer syndromes.

25%

Liver Diseases & Viral Hepatitis

Hepatitis B (HBV DNA, surface antigen serology, antiviral therapy) and Hepatitis C direct-acting antivirals (DAAs) and post-cure follow-up; MASLD/MASH (steatotic liver disease); autoimmune hepatitis, primary biliary cholangitis (PBC), and primary sclerosing cholangitis (PSC); drug-induced liver injury (DILI); Wilson disease and hemochromatosis.

20%

Cirrhosis, Portal Hypertension & Liver Transplantation

Pathophysiology of portal hypertension; acute variceal hemorrhage (somatostatin/octreotide, EVL, TIPS, balloon tamponade); ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS-AKI); hepatic encephalopathy; hepatocellular carcinoma (HCC) screening (BCLC staging); liver transplantation indications (MELD-Na score) and complications.

15%

Pancreatobiliary Disorders & Diagnostic/Therapeutic Endoscopy

Acute pancreatitis (Atlanta classification, etiology, fluid resuscitation, necrosectomy) and chronic pancreatitis; choledocholithiasis, cholangitis (Tokyo guidelines), and biliary strictures; cystic neoplasms of the pancreas; endoscopic ultrasound (EUS) and ERCP indications and complications.

Preparing for the Egyptian Board Gastroenterology & Hepatology Exam

What You Need to Know

  • Passing score: Set by psychometric standard-setting (Angoff/Hofstee method); no fixed percentage published
  • Assessment: The Egyptian Board Gastroenterology and Hepatology examination comprises three stages: Part 1 features written multiple-choice questions assessing GI physiology, hepatic anatomy/blood flow, pathology, microbiology, and pharmacology. Part 2 features advanced clinical multiple-choice examinations evaluating real-world diagnostic algorithms, BCLC staging for HCC, IBD biologic sequencing, and acute variceal bleed management. Part 3 is a comprehensive clinical examination consisting of objective structured clinical examination (OSCE) stations, patient consultations, endoscopic video interpretation, and viva voce with senior academic examiners. Note that Part Three is entirely clinical, and the official board does not publish a standardized MCQ question count. This 100-question practice set is an English-language study aid dedicated to reinforcing key cognitive knowledge across Parts 1 and 2.
  • Time limit: Varies by examination part
  • Exam / certification fees: Prescribed by Egyptian Health Council regulatory bylaws Official sources

Using Our Practice Resources

  • Work through all 100 available questions
  • Review every answer and explanation
  • Track weak areas and revisit them
  • Use our AI tutor for tough concepts

Egyptian Board Gastroenterology & Hepatology: Suggested Study Strategy

1Review updated EASL and AASLD guidelines for managing viral hepatitis B and C, steatotic liver disease (MASLD), and decompensated cirrhosis.
2Master the management algorithms for acute upper GI bleeding (Glasgow-Blatchford score, pre-endoscopic erythromycin/octreotide, and EVL vs hemospray).
3Consolidate IBD biologic and small molecule therapeutics (anti-TNF, anti-integrin, anti-IL12/23, JAK inhibitors) and monitoring strategies (calprotectin, therapeutic drug monitoring).
4Understand diagnostic criteria and management of hepatorenal syndrome (HRS-AKI), SBP prophylaxis, and refractory ascites.

Frequently Asked Questions

What is the official question count for the Egyptian Board Gastroenterology exam?

The Egyptian Health Council does not publish a fixed, standardized question count for its written examination stages. Part 1 and Part 2 written papers typically contain 100 to 200 items per diet. This platform provides 100 curated practice MCQs covering high-yield curriculum objectives.

Does this practice test cover practical endoscopy (Part 3)?

Part 3 is a clinical and oral examination involving live patients, endoscopic video reviews, and viva voce. This practice test is dedicated to mastering the theoretical and diagnostic knowledge tested in Parts 1 and 2.

What standard textbooks and guidelines are emphasized?

Recommended sources include Sleisenger and Fordtran's Gastrointestinal and Liver Disease, EASL Clinical Practice Guidelines, and ACG/AGA Guidelines.